FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN® dual-masked T-cell ...

The former president announced last year he has an aggressive form of prostate cancer. He and his aides say he’s doing well and has upcoming public appearances.

Metastasis-directed therapy for oligometastatic prostate cancer was associated with improved outcomes in a systematic review and meta-analysis.

Adding metastasis-directed therapy (MDT) to standard of care was tied to improvements in several survival endpoints in oligometastatic prostate cancer, a recent analysis suggests.

When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...

Feb 23 (Reuters) - Japan's Astellas and Vir Biotechnology said on Monday they will together develop and commercialize the U.S. drug developer's prostate cancer experimental drug. Vir will receive $335 ...

Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

CNN — (CNN) — President Joe Biden’s diagnosis of metastatic prostate cancer has understandably raised concerns and questions: How long has he had cancer, how will he be treated, and what is his ...

Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date - Dose-dependent anti-tumo ...